Simplex Trading’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-23,401
Closed -$521K 9567
2025
Q4
$503K Sell
23,401
-38,292
-62% -$672K ﹤0.01% 3297
2025
Q3
$722K Buy
61,693
+34,094
+124% +$339K ﹤0.01% 3383
2025
Q2
$256K Buy
27,599
+15,445
+127% +$127K ﹤0.01% 4241
2025
Q1
$81K Buy
12,154
+5,874
+94% +$56.4K ﹤0.01% 5283
2024
Q4
$66K Buy
6,280
+4,954
+374% +$59.9K ﹤0.01% 5575
2024
Q3
$19K Buy
+1,326
New +$18.8K ﹤0.01% 6710
2024
Q2
Sell
-3,165
Closed -$49.5K 9262
2024
Q1
$78K Buy
3,165
+448
+16% +$9.09K ﹤0.01% 5845
2023
Q4
$29K Sell
2,717
-12,222
-82% -$102K ﹤0.01% 6591
2023
Q3
$124K Sell
14,939
-1,865
-11% -$13.7K ﹤0.01% 4874
2023
Q2
$132K Buy
16,804
+10,381
+162% +$56.8K ﹤0.01% 4750
2023
Q1
$32K Buy
6,423
+453
+8% +$2.21K ﹤0.01% 6423
2022
Q4
$13K Buy
5,970
+2,328
+64% +$9.38K ﹤0.01% 7289
2022
Q3
$16K Buy
3,642
+1,679
+86% +$7.87K ﹤0.01% 7757
2022
Q2
$6K Buy
+1,963
New +$7.14K ﹤0.01% 8722
2022
Q1
Sell
-6,086
Closed -$45.5K 10857
2021
Q4
$78K Buy
6,086
+5,986
+5,986% +$107K ﹤0.01% 6624
2021
Q3
$1K Hold
100
﹤0.01% 9644
2021
Q2
$1K Buy
+100
New +$2.21K ﹤0.01% 9822

Other funds holding IMNM

Simplex Trading's IMNM Position: Q1 2026 in Review

Simplex Trading sold out of Immunome (IMNM) in Q1 2026, closing a stake of 23,401 shares — an estimated $521K sold.

Simplex Trading first reported a position in IMNM in Q2 2021 and held it in 17 quarters. The position peaked at $722K in Q3 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Simplex Trading reported no remaining Immunome position as of Q1 2026 after selling out during the quarter.
  • Simplex Trading sold 23,401 Immunome shares in Q1 2026, an estimated $521K.
  • Simplex Trading first reported a position in Immunome in Q2 2021 and held it in 17 quarters.
  • Simplex Trading's Immunome position peaked at $722K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.